Optimizing hypomethylating agents in myelodysplastic syndromes.

  title={Optimizing hypomethylating agents in myelodysplastic syndromes.},
  author={Raphael Itzykson and Pierre Fenaux},
  journal={Current opinion in hematology},
  volume={19 2},
PURPOSE OF REVIEW Hypomethylating agents (HMAs) improve the outcome of higher-risk myelodysplastic syndromes (MDS) and provide multilineage response in lower-risk patients but their results must be optimized, especially as the poor outcome of patients after HMA failure is now established. RECENT FINDINGS Current efforts include evaluation of novel outpatient administration schedules and routes, improving compliance and drug exposure to reach continuous hypomethylation. Novel combination… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-9 of 9 extracted citations

Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia.

Journal of clinical pharmacy and therapeutics • 2015
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…